The antioxidant function of the p53 tumor suppressor

Nature Medicine

Volumn 11, Issue 12, 2005, Pages 1306-1313

  Sablina, Anna A ^a,b,d,e   Budanov, Andrei V ^a,c,d,e   Ilyinskaya, Galina V ^a,b   Agapova, Larissa S ^b   Kravchenko, Julia E ^a,c   Chumakov, Peter M ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Cancer Research Center   (Russian Federation)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DIET SUPPLEMENTATION; DNA DAMAGE; DOWN REGULATION; FUNCTIONAL PROTEOMICS; GENE FUNCTION; GENOME; GROWTH INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; KARYOTYPING; KNOCKOUT MOUSE; LUNG CANCER; LYMPHOMA; MOUSE; MUTATION RATE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION;

ACETYLCYSTEINE; ANIMALS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEOXYGUANOSINE; DNA DAMAGE; DNA PRIMERS; GENE EXPRESSION REGULATION; GENETIC VECTORS; GENOMIC INSTABILITY; HUMANS; KARYOTYPING; LENTIVIRUS; MICE; MODELS, BIOLOGICAL; MUTAGENESIS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SPLEEN; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 28644447272     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1320     Document Type: Article

References (49)

1. Lane, D.P. p53, guardian of the genome. Nature 358, 15-16 (1992).
2. Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev. 82, 47-95 (2002).
3. Finkel, T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 15, 247-254 (2003).
4. Jackson, A.L. & Loeb, L.A. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat. Res. 477, 7-21 (2001).
5. Klungland, A. et al. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc. Natl. Acad. Sci. USA 96, 13300-13305 (1999).
6. Beckman, K.B. & Ames, B.N. Oxidative decay of DNA. J. Biol. Chem. 272, 19633-19636 (1997).
7. Macip, S. et al. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol. Cell. Biol. 23, 8576-8585 (2003).
8. Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W. & Vogelstein, B. A model for p53-induced apoptosis. Nature 389, 300-305 (1997).
9. Tan, M. et al. Transcriptional activation of the human glutathione peroxidase promoter by p53. J. Biol. Chem. 274, 12061-12066 (1999).
10. Hussein, S.P. et al. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res. 64, 2350-2356 (2004).
11. Yoon, K.A., Nakamura, Y. & Arakawa, H. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J. Hum. Genet. 49, 134-140 (2004).
12. Budanov, A.V., Sablina, A.A., Feinstein, E., Koonin, E.V. & Chumakov, P.M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304, 596-600 (2004).
13. Agarwal, M.L., Agarwal, A., Taylor, W.R. & Stark, G.R. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 92, 8493-8497 (1995).
14. Ossovskaya, V.S. et al. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc. Natl. Acad. Sci. USA 93, 10309-10314 (1996).
15. Florenes, V.A. et al. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J. Natl. Cancer Inst. 86, 1297-1302 (1994).
16. Velasco-Miguel, S. et al. PA26, a novel target for the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 18, 127-137 (1999).
17. Lin, J., Chen, J., Elenbaas, B. & Levine, A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246 (1994).
18. Osovskaia, V.S. et al. Effect of on various cell lines of p53 cDNA, expressed under the control of an exogenous homologous promotor. Mol Biol (Mosk) 29, 61-70 (1995).
19. Kovar, H. et al. Characterization of distinct consecutive phases in non-genotoxic p53-induced apoptosis of Ewing tumor cells and the rate-limiting role of caspase 8. Oncogene 19, 4096-4107 (2000).
20. King, M.P. & Attardi, G. Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA. Cell 52, 811-819 (1988).
21. Griffiths, S.D. et al. Absence of p53 permits propagation of mutant cells following genotoxic damage. Oncogene 14, 523-531 (1997).
22. Havre, P.A., Yuan, J., Hedrick, L., Cho, K.R. & Glazer, P.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 55, 4420-4424 (1995).
23. Bishop, A.J. et al. Atm-, p53-, and Gadd45a-deficient mice show an increased frequency of homologous recombination at different stages during development. Cancer Res. 63, 5335-5343 (2003).
24. Knaap, A.G. & Simons, J.W. A mutational assay system for L5178Y mouse lymphoma cells, using hypoxanthine-guanine-phosphoribosyl-transferase (HGPRT)-deficiency as marker. The occurrence of a long expression time for mutations induced by X-rays and EMS. Mutat. Res. 30, 97-110 (1975).
25. Donehower, L.A. et al. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol. Carcinog. 14, 16-22 (1995).
26. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
27. Wahl, G.M., Linke, S.P., Paulson, T.G. & Huang, L.C. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv. 29, 183-219 (1997).
28. Fukasawa, K., Wiener, F., Vande Woude, G.F. & Mai, S. Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 15, 1295-1302 (1997).
29. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7 (1994).
30. Zurer, I. et al. The role of p53 in base excision repair following genotoxic stress. Carcinogenesis 25, 11-19 (2004).
31. Seo, Y.R. & Jung, H.J. The potential roles of p53 tumor suppressor in nucleotide excision repair (NER) and base excision repair (BER). Exp. Mol. Med. 36, 505-509 (2004).
32. Achanta, G. & Huang, P. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res. 64, 6233-6239 (2004).
33. Deng, C., Zhang, P., Harper, J.W., Elledge, S.J. & Leder, P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684 (1995).
34. Villunger, A. et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302, 1036-1038 (2003).
35. Jeffers, J.R. et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321-328 (2003).
36. Kim, H.J. et al. Modulation of redox-sensitive transcription factors by calorie restriction during aging. Mech. Ageing Dev. 123, 1589-1595 (2002).
37. Sohal, R.S., Agarwal, S., Candas, M., Forster, M.J. & Lal, H. Effect of age and caloric restriction on DNA oxidative damage in different tissues of C57BL/6 mice. Mech. Ageing Dev. 76, 215-224 (1994).
38. Hursting, S.D., Perkins, S.N. & Phang, J.M. Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc. Natl. Acad. Sci. USA 91, 7036-7040 (1994).
39. Hursting, S.D. et al. Diet-gene interactions in p53-deficient mice: insulin-like growth factor-1 as a mechanistic target. J. Nutr. 134, 2482S-2486S (2004).
40. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S. & Vande Woude, G.F. Abnormal centrosome amplification in the absence of p53. Science 271, 1744-1747 (1996).
41. Agapova, L.S. et al. Chromosome changes caused by alterations of p53 expression. Mutat. Res. 354, 129-138 (1996).
42. Reliene, R., Fischer, E. & Schiestl, R.H. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res. 64, 5148-5153 (2004).
43. Xu, Y. et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10, 2411-2422 (1996).
44. Schubert, R. et al. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum. Mol. Genet. 13, 1793-1802 (2004).
45. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
46. Li, F.P. et al. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J. Natl. Cancer Inst. 84, 1156-1160 (1992).
47. Bond, G.L. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 (2004).
48. Neumann, C.A. et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424, 561-565 (2003).
49. Balansky, R., Izzotti, A., Scatolini, L., D'Agostini, F. & De Flora, S. Induction by carcinogens and chemoprevention by N-acetylcysteine of adducts to mitochondrial DNA in rat organs. Cancer Res. 56, 1642-1647 (1996).